The DOI matches its Crossref record; 91 of the 92 references it cites were found in a registry or an index.
Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response
Open accessAbstract
mRNA vaccine platforms present numerous advantages, such as versatility, rapid production, and induction of cellular and humoral responses. Moreover, mRNAs have inherent adjuvant properties due to their complex interaction with pattern recognition receptors (PRRs). This recognition can be either beneficial in activating antigen-presenting cells (APCs) or detrimental by indirectly blocking mRNA translation. To decipher this Janus effect, we describe the different innate response mechanisms triggered by mRNA molecules and how each element from the 5' cap to the poly-A tail interferes with innate/adaptive immune responses. Then, we emphasize the importance of some critical steps such as production, purification, and formulation as key events to further improve the quality of immune responses and balance innate and adaptive immunity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is known that UTRs are associated with processes of mRNA translation, and by interacting with RNA-binding proteins (RBPs) and microRNAs, UTRs can influence mRNA’s translation efficiency and resistance to degradation [3,4,5,6,7].”
From Untranslated Region Sequences and the Efficacy of mRNA Vaccines against Tuberculosis (2024) · cites this paper as [4]
In the citing paper
“The use of CleanCap® cap analogs reduces the probability of reverse capped, uncapped, and cap0 intermediates, and the co-transcribed mRNA only possesses a cap1 structure, therefore capping rate can be 90% or higher.52,126”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [52]
In the citing paper
“The vaccinia capping enzyme (VCE) integrates the enzymatic activity of RTPase, GTase, and G-N7 MTase, which can be capped to generate a cap0 structure, and then 2′-O-MTase can be used to generate a methylated cap1 structure, thus reaching a capping efficiency of 100%.52”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [52]
In the citing paper
“dsRNA can activate PRR such as TLR3,52,156 whereas ssRNA activates TLR7 and TLR8 to produce IFN-I, thus inducing inflammation in the host and interrupting mRNA translation.157,158”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [52]
In the citing paper
“Currently, nucleoside-modified mRNA vaccines employ 100% chemically modified nucleosides replacing natural nucleosides, and m1ψ is often used to replace uridine during IVT to improve the safety and stability of mRNA vaccines.52,134,172”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [52]
In the citing paper
“Uridine depletion to reduce counterproductive immune reactions can be achieved by the replacement of uridine by codon optimization, but this must be balanced with regard to transfer RNA abundance.120, 121, 122”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [120]
In the citing paper
“The optimization of mRNA constructs, including the coding sequence, can regulate immunogenicity without incorporation of modified nucleosides.”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [120]
In the citing paper
“Further, the 5′ cap protects the mRNA sterically from degradation by exonucleases, and it works synergistically with the poly(A) tail at the 3′ end, poly(A) binding proteins and translation initiation factor proteins to circularize mRNA and recruit ribosomes for initiating translation10,11.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [11]
In the citing paper
“A sufficiently long tail (100–150 bp) is necessary to interact with poly(A) binding proteins that form complexes necessary for initiating translation11,12 and protecting the cap from degradation by decapping enzymes13.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [11]
In the citing paper
“These engineered UTR sequences minimize mRNA degradation by excluding miRNA-binding sites11 and AU-rich regions in the 3′ UTR19.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [11]
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
5'-Triphosphate RNA Is the Ligand for RIG-I
Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.-K., Schlee, M., et al. (2006) · Science · doi:10.1126/science.1132505 · Cited by 2,474
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Kato, H., Takeuchi, O., Mikamo, E., Hirai, R., Kawai, T., Matsushita, K., Hiiragi, A., Dermody, T. S., Fujita, T., & Akira, S. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080091 · Cited by 1,649
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
mRNA capping: biological functions and applications
Ramanathan, A., Robb, G. B., & Chan, S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw551 · Cited by 961
Flagged first, then by citations
1 of the 92 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 376
mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!
Chavda, V. P., Jogi, G., Dave, S., Patel, B. M., Nalla, L. V., & Koradia, K. D. (2023) · Vaccines · doi:10.3390/vaccines11030507 · Cited by 39
Zhang, J., Liu, Y., Li, C., Xiao, Q., Zhang, D., Chen, Y., Rosenecker, J., Ding, X., & Guan, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092182 · Cited by 39
Hourdel, L., Lebaz, N., Peral, F., Ripoll, M., Briançon, S., Bensaid, F., Luthra, S., & Cogné, C. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125297 · Cited by 37
Digital Twins for Continuous mRNA Production
Helgers, H., Hengelbrock, A., Schmidt, A., & Strube, J. (2021) · Processes · doi:10.3390/pr9111967 · Cited by 37
Effect of DMARDs on the immunogenicity of vaccines
van Sleen, Y., van der Geest, K. S. M., Huckriede, A. L. W., van Baarle, D., & Brouwer, E. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-00992-8 · Cited by 37
Tuberculosis vaccines and therapeutic drug: challenges and future directions
An, Y., Ni, R., Li, Z., Yang, L., Ye, Z., Li, L., Parkkila, S., Aspatwar, A., & Gong, W. (2025) · Molecular Biomedicine · doi:10.1186/s43556-024-00243-6 · Cited by 38
Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases
Rouf, N. Z., Biswas, S., Tarannum, N., Oishee, L. M., & Muna, M. M. (2022) · RNA Biology · doi:10.1080/15476286.2022.2055923 · Cited by 39
Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics
Yang, W., Cao, J., Cheng, H., Chen, L., Yu, M., Chen, Y., & Cui, X. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.11.014 · Cited by 36
mRNA Synthesis and Encapsulation in Ionizable Lipid Nanoparticles
McKenzie, R. E., Minnell, J. J., Ganley, M., Painter, G. F., & Draper, S. L. (2023) · Current Protocols · doi:10.1002/cpz1.898 · Cited by 38
Vaccine process technology—A decade of progress
Buckland, B. C., Sanyal, G., Ranheim, T., Pollard, D. J., Searles, J. A., Behrens, S., Pluschkell, S. B., Josefsberg, J. O., & Roberts, C. J. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28703 · Cited by 35
Huang, M., Cha, Z., Liu, R., Lin, M., Gafoor, N. A., Kong, T., Ge, F., & Chen, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1399926 · Cited by 36
Emerging advances in delivery systems for mRNA cancer vaccines
Jiang, Z., Xu, Y., Du, G., & Sun, X. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.04.039 · Cited by 35
Laila, U. E., An, W., & Xu, Z.-X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1448489 · Cited by 34
Meany, E. L., Klich, J. H., Jons, C. K., Mao, T., Chaudhary, N., Utz, A., Baillet, J., Song, Y. E., Saouaf, O. M., Ou, B. S., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr2631 · Cited by 37
Advances and prospects of mRNA vaccines in cancer immunotherapy
Liu, Y., Yan, Q., Zeng, Z., Fan, C., & Xiong, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189068 · Cited by 33
Nucleic acid drug and delivery techniques for disease therapy: Present situation and future prospect
Wang, T., Tang, Y., Tao, Y., Zhou, H., & Ding, D. (2024) · Interdisciplinary medicine · doi:10.1002/inmd.20230041 · Cited by 33
Untranslated Region Sequences and the Efficacy of mRNA Vaccines against Tuberculosis
Reshetnikov, V., Terenin, I., Shepelkova, G., Yeremeev, V., Kolmykov, S., Nagornykh, M., Kolosova, E., Sokolova, T., Zaborova, O., Kukushkin, I., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020888 · Cited by 33
Precision-engineering of subunit vaccine particles for prevention of infectious diseases
Chen, S., Pounraj, S., Sivakumaran, N., Kakkanat, A., Sam, G., Kabir, M. T., & Rehm, B. H. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1131057 · Cited by 32
Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders
Arjunan, P., Kathirvelu, D., Mahalingam, G., Goel, A., Zacharaiah, U. G., Srivastava, A., & Marepally, S. K. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.015 · Cited by 33
RNA Nanomedicine: Delivery Strategies and Applications
Byun, J., Wu, Y., Park, J.-W., Kim, J. S., Li, Q., Choi, J., Shin, N., Lan, M., Cai, Y., Lee, J., et al. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00860-z · Cited by 32
Mukhtar, M., Wajeeha, A. W., Zaidi, N. U. S. S., & Bibi, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213911 · Cited by 31
Advances in Nonviral mRNA Delivery Materials and Their Application as Vaccines for Melanoma Therapy
Neill, B., Romero, A. R., & Fenton, O. S. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00721 · Cited by 31
Comparative immunopathogenesis and biology of recently discovered porcine circoviruses
Rakibuzzaman, A., & Ramamoorthy, S. (2021) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14244 · Cited by 29
Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases
Iyer, S., Yadav, R. T., Agarwal, S., Tripathi, S., & Agarwal, R. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00123-21 · Cited by 20
mRNA-based therapeutic strategies for cancer treatment
Taibi, T., Cheon, S., Perna, F., & Vu, L. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.035 · Cited by 31
New-Onset Systemic Lupus Erythematosus after mRNA SARS-CoV-2 Vaccination
Báez-Negrón, L., & Vilá, L. M. (2022) · Case Reports in Rheumatology · doi:10.1155/2022/6436839 · Cited by 28
Caliskan, I., Buluş, E., Afşar, N., & Altıntaş, A. (2022) · The Neurologist · doi:10.1097/nrl.0000000000000420 · Cited by 28
mRNA vaccines: A novel weapon to control infectious diseases
Tian, Y., Deng, Z., & Yang, P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1008684 · Cited by 29
The mRNA vaccine, a swift warhead against a moving infectious disease target
Mir, S., & Mir, M. A. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2320327 · Cited by 28
mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy
Shariati, A., Khani, P., Nasri, F., Afkhami, H., Khezrpour, A., Kamrani, S., Shariati, F. S., Alavimanesh, S., & Modarressi, M. H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00692-9 · Cited by 27
Gong, N., Kim, D., Alameh, M., El-Mayta, R. D., Han, E. L., Dwivedi, G., Palanki, R., Shi, Q., Han, X., Xue, L., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01422-8 · Cited by 34
Application of mRNA Technology in Cancer Therapeutics
Eralp, Y. (2022) · Vaccines · doi:10.3390/vaccines10081262 · Cited by 27
Lu, Y., Qian, C., Huang, Y., Ren, T., Xie, W., Xia, N., & Li, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145501 · Cited by 28
mRNA vaccines: immunogenicity and quality characteristics
Quan, Y., Yang, H., Li, W., & Li, L. X. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03800-5 · Cited by 27
Universal Flu mRNA Vaccine: Promises, Prospects, and Problems
Deviatkin, A. A., Simonov, R. A., Trutneva, K. A., Maznina, A. A., Khavina, E. M., & Volchkov, P. (2022) · Vaccines · doi:10.3390/vaccines10050709 · Cited by 26
RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System
de Mey, W., Esprit, A., Thielemans, K., Breckpot, K., & Franceschini, L. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3304 · Cited by 27
İmani, S., Tagit, O., & Pichon, C. (2024) · npj Vaccines · doi:10.1038/s41541-024-00807-1 · Cited by 25
RetractedCancer mRNA vaccines: clinical application progress and challenges
Li, H., Min, L., Du, H., Wei, X., & Tong, A. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217752 · Cited by 26
Ji, A., Xu, M., Pan, Y., Diao, L., Ma, L., Li, Q., Cheng, J., & Liu, M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03445-1 · Cited by 24
Vaccines and Autoimmunity—From Side Effects to ASIA Syndrome
Seida, I., Seida, R., Elsalti, A., & Mahroum, N. (2023) · Medicina · doi:10.3390/medicina59020364 · Cited by 24
Advancing Cancer Immunotherapy: The Potential of mRNA Vaccines As a Promising Therapeutic Approach
Goyal, F., Chattopadhyay, A., Navik, U., Jain, A., Reddy, P. H., Bhatti, G. K., & Bhatti, J. S. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300255 · Cited by 25
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
mRNA Technology and Mucosal Immunization
Toniolo, A., Maccari, G., & Camussi, G. (2024) · Vaccines · doi:10.3390/vaccines12060670 · Cited by 23
mRNA medicine: Recent progresses in chemical modification, design, and engineering
Hou, X., Shi, J., & Xiao, Y. (2024) · Nano Research · doi:10.1007/s12274-024-6978-6 · Cited by 24
mRNA delivery technologies: Toward clinical translation
Gómez-Aguado, I., Rodríguez-Castejón, J., Beraza-Millor, M., Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.010 · Cited by 23
Harnessing RNA Technology to Advance Therapeutic Vaccine Antigens against Chagas Disease
Mancino, C., Pollet, J. B. K., Zinger, A., Jones, K. M., Villar, M. J., Leão, A. C., Adhikari, R., Versteeg, L., Kundu, R. T., Strych, U., et al. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c18830 · Cited by 23
mRNA Vaccines: Current Applications and Future Directions
Li, J., Liu, Y., Dai, J., Li, Y., Xiong, F., Xia, J., Jin, J., Wu, Y., & Peng, X. (2025) · MedComm · doi:10.1002/mco2.70434 · Cited by 27
Co-Delivery of mRNA and pDNA Using Thermally Stabilized Coacervate-Based Core-Shell Nanosystems
Nasr, S. S., Lee, S., Thiyagarajan, D., Boese, A. S., Loretz, B., & Lehr, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111924 · Cited by 22
Imaging-guided/improved diseases management for immune-strategies and beyond
Zhang, T., Guo, S., Li, F., Lan, X., Jia, Y., Zhang, J., Huang, Y., & Liang, X. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114446 · Cited by 22
The clinical progress and challenges of mRNA vaccines
Yu, M., Wang, N., Zhu, J., & Lin, Y. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1894 · Cited by 23
Advancing mRNA vaccines for infectious diseases: key components, innovations, and clinical progress
Li, S., Zheng, L., Zhong, J., & Gao, X. (2025) · Essays in Biochemistry · doi:10.1042/ebc20253009 · Cited by 22
mRNA Vaccine - A New Cancer Treatment Strategy
Tan, T., Deng, S., Wu, B.-H., Yang, Q., Wu, M., Wu, H., Cao, C., & Xu, C. S. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230222124424 · Cited by 22
Research progress on non-protein-targeted drugs for cancer therapy
Zhang, Y., Lu, L., Song, F., Zou, X., Liu, Y., Zheng, X., Qian, J., Gu, C., Huang, P. C., & Yang, Y. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02635-y · Cited by 22
mRNA Vaccine Platform: mRNA Production and Delivery
Litvinova, V. R., Рудометов, А. П., Карпенко, Л. И., & Ilyichev, A. A. (2023) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023020152 · Cited by 26
Sending a Message: Use of mRNA Vaccines to Target the Tumor Immune Microenvironment
Ramirez, F., Zambrano, A., Hennis, R., Holland, N. A., Lakshmanaswamy, R., & Chacon, J. A. (2023) · Vaccines · doi:10.3390/vaccines11091465 · Cited by 21
Nelson, A. L., Mancino, C., Gao, X., Choe, J. A., Chubb, L. S., Williams, K. B., Czachor, M. E., Marcucio, R., Taraballi, F., Cooke, J. P., et al. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.05.020 · Cited by 21
DNA vaccines as promising immuno-therapeutics against cancer: a new insight
Shariati, A., Khezrpour, A., Shariati, F. S., Afkhami, H., Yarahmadi, A., Alavimanesh, S., Kamrani, S., Modarressi, M. H., & Khani, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1498431 · Cited by 21
Methods for nanoparticle synthesis and drug delivery
Choudhury, S., Paul, S. S., Goswami, S., & Deb, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-88450-1.00005-3 · Cited by 23
The Effect of Cholesterol Content on the Adjuvant Activity of Nucleic-Acid-Free Lipid Nanoparticles
Anindita, J., Tanaka, H., Yamakawa, T., Sato, Y., Matsumoto, C., Ishizaki, K., Oyama, T., Suzuki, S., Ueda, K., Higashi, K., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020181 · Cited by 21
Quantification of mRNA cap-modifications by means of LC-QqQ-MS
Muthmann, N., Špaček, P., Reichert, D., van Dülmen, M., & Rentmeister, A. (2021) · Methods · doi:10.1016/j.ymeth.2021.05.018 · Cited by 19
Hengelbrock, A., Schmidt, A., Helgers, H., Vetter, F. L., & Strube, J. (2023) · Processes · doi:10.3390/pr11030745 · Cited by 19
Gu, J., Xu, Z., Liu, Q., Tang, S., Zhang, W., Xie, S., Chen, X., Chen, J., Yong, K., Yang, C., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302409 · Cited by 20
Non-Viral RNA Therapies for Non-Small Cell Lung Cancer and Their Corresponding Clinical Trials
Tiwade, P. B., Fung, V., VanKeulen‐Miller, R., Narasipura, E. A., Ma, Y., & Fenton, O. S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00871 · Cited by 18
CircRNA: Unlocking new frontiers in therapeutic and vaccine development
Bahrulolum, H., Rouzbahani, F. N., Hoseini, Z. S., Chaharmahali, M., & Hosseini, S. M. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.038 · Cited by 19
Physical and chemical advances of synthetic delivery vehicles to enhance mRNA vaccine efficacy
Kim, H. J., Seo, S. K., & Park, H. Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.029 · Cited by 18
Low Resource Integrated Platform for Production and Analysis of Capped mRNA
Nwokeoji, A. O., Chou, T.-C., & Nwokeoji, E. A. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.2c00609 · Cited by 18
The mRNA vaccine platform for veterinary species
Fazel, F., Doost, J. S., Raj, S., Boodhoo, N., Karimi, K., & Sharif, S. (2024) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2024.110803 · Cited by 19
Off the beaten path: Novel mRNA-nanoformulations for therapeutic vaccination against HIV
D’haese, S., Lacroix, C., García, F., Plana, M., Ruță, S. M., Vanham, G. L., Verrier, B., & Aerts, J. L. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.009 · Cited by 18
Self-citationQu, Y., Liu, R., Sun, D., & Dai, Z. (2024) · Materials Chemistry Frontiers · doi:10.1039/d4qm00479e · Cited by 18
Zhao, Y., Chen, X., Zhang, X., & Liu, H. (2025) · Biomarker Research · doi:10.1186/s40364-025-00794-y · Cited by 18
Yang, Y., Sun, Y., Kang, X., & Wang, Y. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2597629 · Cited by 17
mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People
Garbuglia, A. R., Minosse, C., & Porto, P. D. (2022) · Viruses · doi:10.3390/v14040748 · Cited by 17
mRNA therapeutics for disease therapy: principles, delivery, and clinical translation
Zhou, D., Wang, K., Zhang, Y., Ma, K., Yang, X., Li, Z.-Y., Yu, S., Chen, K., & Qiao, S. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02782h · Cited by 18
Guo, X., Liu, D., Huang, Y., Deng, Y., Wang, Y., Mao, J., Zhou, Y., Xiong, Y., & Gao, X. (2023) · Virology Journal · doi:10.1186/s12985-023-02023-0 · Cited by 19
Delivery of mRNA for cancer therapy: progress and prospects
Su, L.-J., Xu, M.-X., Ji, Z.-H., Zhu, J.-Q., Yu, M., Wang, Y., & Lin, Y. (2023) · Nano Today · doi:10.1016/j.nantod.2023.102013 · Cited by 17
Idiopathic nephrotic syndrome relapse following COVID-19 vaccination: a series of 25 cases
Hummel, A., Oniszczuk, J., Kervella, D., Charbit, M., Guerrot, D., Testa, A., Philipponnet, C., Chauvet, C., Guincestre, T., Brochard, K., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac134 · Cited by 17
mRNA vaccine development and applications: A special focus on tumors (Review)
Chen, B., Yang, Y., Wang, X., Yang, W., Lu, Y., Wang, D., Zhuo, E., Tang, Y., Su, J., Tang, G., et al. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5669 · Cited by 17
Better, Faster, Stronger: Accelerating mRNA ‐Based Immunotherapies With Nanocarriers
Carvalho, H., Fidalgo, T. A. S., Acúrcio, R. C., Matos, A. I., Satchi‐Fainaro, R., & Florindo, H. F. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.2017 · Cited by 16
Wang, J., Huang, S., Wei, H., Liang, S., Ding, Y., Xiao, Z., & Shuai, X. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.04.039 · Cited by 16
Research progress of mRNA vaccines for infectious diseases
Zhang, Z., Du, J., Zhang, D., Han, R., Wu, X., & Liang, Y. (2025) · European journal of medical research · doi:10.1186/s40001-025-03060-x · Cited by 19
Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy
Su, L., Pan, W., Li, X., Zhou, X., Ma, X., & Min, Y. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.12.039 · Cited by 16
Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review
Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 16
Wang, Q., Song, Z., Yang, J., He, Q., Mao, Q., Bai, Y., Liu, J., An, C., Yan, X., Cui, B., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2059404 · Cited by 16
Innate sensing of mRNA vaccines
Wuebben, C., Bartok, E., & Hartmann, G. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102249 · Cited by 16
Advances and Strategies in Enhancing mRNA Cancer Vaccines
Zhang, M., Chen, S., Hu, H.-J., Ong, Y., & Ni, Q. (2025) · Advanced Materials · doi:10.1002/adma.202509880 · Cited by 17
RNA Engineering for Public Health: Innovations in RNA-Based Diagnostics and Therapeutics
Thavarajah, W., Hertz, L. M., Bushhouse, D. Z., Archuleta, C. M., & Lucks, J. B. (2021) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-101420-014055 · Cited by 15
Optimization of an LNP-mRNA vaccine candidate targeting SARS-CoV-2 receptor-binding domainPreprint
Kobiyama, K., Imai, M., Jounai, N., Nakayama, M., Hioki, K., Iwatsuki‐Horimoto, K., Yamayoshi, S., Tsuchida, J., Niwa, T., Suzuki, T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.04.433852 · Cited by 15
In Situ Chimeric Antigen Receptor Macrophage Therapy via Co-Delivery of mRNA and Immunostimulant
Han, J., Fagan, E., Yeom, K., & Park, J. (2025) · ACS Nano · doi:10.1021/acsnano.5c09138 · Cited by 15
Process and analytical strategies for the safe production of mRNA vaccines and therapeutics
Nowak, C. J. A., Liu, S., Falconer, R. J., & Gerstweiler, L. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11455-0 · Cited by 16
Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines
Alesci, A., Gitto, M., Kotańska, M., Cascio, P. L., Miller, A., Nicosia, N., Fumia, A., & Pergolizzi, S. (2022) · Human Immunology · doi:10.1016/j.humimm.2022.08.004 · Cited by 14
Advances in Development of mRNA-Based Therapeutics
Huang, L., Zhang, L., Li, W., Li, S., Wen, J., Li, H., & Liu, Z. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_222 · Cited by 16
Recent advances in research on biointerfaces: From cell surfaces to artificial interfaces
Hori, K., Yoshimoto, S., Yoshino, T., Zako, T., Hirao, G., Fujita, S., Nakamura, C., Yamagishi, A., & Kamiya, N. (2022) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2021.12.004 · Cited by 14
Kálai, T., Pongracz, J. E., & Mátyus, P. (2022) · Chemistry · doi:10.3390/chemistry4020019 · Cited by 14
Message in a bottle: mRNA vaccination for influenza
Shartouny, J. R., & Lowen, A. C. (2022) · Journal of General Virology · doi:10.1099/jgv.0.001765 · Cited by 15
A self-amplifying mRNA vaccine expressing PRV gD induces robust immunity against virulent mutants
Ling, T., Zhang, X., Huan-huan, L., Ya-Ting, Z., Ya-mei, L., RongLi, G., DAMIANI, A. M., Sai-Sai, C., Chuan-jian, Z., Rui, D., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01251-5 · Cited by 13
Yuan, X., Wu, Z., Guo, J., Luo, D., Li, T., Cao, Q., Ren, X., Fang, H., Xu, D., & Cao, Y. (2023) · Advanced Materials · doi:10.1002/adma.202303321 · Cited by 13
Innate immune response restarts adaptive immune response in tumors
Li, W.-S., Zhang, Q., Li, Q., Liu, S.-Y., Yuan, G.-Q., & Pan, Y.-W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1260705 · Cited by 14
A landscape review of malaria vaccine candidates in the pipeline
Tajudeen, Y. A., Oladipo, H. J., Yusuff, S. I., Abimbola, S. O., Abdulkadir, M., Oladunjoye, I. O., Omotosho, A. O., Egbewande, O. M., Shittu, H. D., Yusuf, R. O., et al. (2024) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-024-00222-3 · Cited by 13
Shi, H., Zhu, Y., Shang, K., Tian, T., Yin, Z., Shi, J., He, Y., Ding, J., Wang, Q., & Zhang, F. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307877 · Cited by 13
Wei, Z., Zhang, S., Wang, X., Xue, Y., Dang, S., & Zhai, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1524317 · Cited by 16
Metadata
- Authors
- Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B.
- Affiliations
- Lyon 1 Université (FR)
- Corresponding author
- Verrier, Bernard
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 26
- Issue
- 3
- Pages
- 311-323
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W2986812831
- Cited by
- 376
- References
- 92
- Citations by year
- 2026: 43 · 2025: 67 · 2024: 65 · 2023: 69 · 2022: 76 · 2021: 47 · 2020: 9
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Trends in Molecular Medicine (acceptedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- EuroNanoMed III
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales
- Fondation Mérieux
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- mRNA vaccines, innate immune response, adaptive immune response, pattern recognition receptors, antigen-presenting cells, 5' cap, poly(A) tail, mRNA translation inhibition, vaccine formulation
- MeSH terms
- mRNA Vaccines, Animals, Humans, Immunity, Innate, RNA, Messenger, Vaccines, Synthetic, Receptors, Pattern Recognition, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
